Navigation Links
DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3)

a collected to date, and the pending completion of the EDEMA4 confirmatory trial already underway, we believe we will be well positioned to apply for regulatory approval to bring to market this much needed therapy for the HAE patient community. The results, which will be presented next week in more detail, highlight the potential of DX-88 to be a safe and efficacious therapy. Ultimately, we believe DX-88 will greatly improve the quality of life of HAE patients worldwide."

EDEMA3 Trial

EDEMA3, the 72-patient, placebo-controlled, multi-center, Phase 3 trial, was conducted at 34 sites in the United States, Europe, Canada, and Israel. The primary objective of EDEMA3 was to determine the efficacy and safety of the fixed 30 mg subcutaneous (SC) dose of DX-88 for patients suffering from moderate to severe acute HAE attacks. The trial had two phases: a double-blind, placebo-controlled phase and a repeat dosing phase. In the first phase, HAE patients received either a single 30 mg SC dose of DX-88 or placebo. After patients received one treatment in the placebo-controlled portion of the study, they were eligible for the second, open-label phase of the study, where they receive repeat dosing with SC DX-88 for any subsequent attacks.

Webcast Presentation Details

Dyax Corp. will host a webcast presentation on Tuesday, April 17, 2007, which will include a discussion of the EDEMA3 results and the patient reported outcome methodology in more detail. Henry E. Blair, Chairman and CEO of Dyax, will be joined by senior management and clinical trial investigators from the EDEMA3 trial.

Date: Tuesday, April 17, 2007

Time: 12:30 p.m. ET

Online Access: Go to the Investor Relations section of the Dyax website (www.dyax.com) and follow instructions for accessing the live webcast. Participants may register in advance.

Telephone Access: Domestic callers, dial 1-888-396-2384

International callers, dial 617-847-8711

Passcode
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
3. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
7. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
8. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
Post Your Comments:
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical Research, ... and obesity, announced today a new textbook,  Translational Research ... by Springer, a leading global scientific publisher. ... illustrate techniques for use in early phase clinical studies ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( ... "Infectious Disease Diagnostics Market by Product, Application, Technology, End ... their offering. , The infectious disease diagnostics ... to reach $18,156.2 million by 2019 from $12,422.8 million ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the ... Product & by End User - Global Forecast to 2019" ... allergy diagnostics market is valued at $1,228.58 million in 2014 ... to reach $2,230.72 million by 2019. Allergy diagnostics is used ...
Breaking Medicine Technology:New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... , ATLANTA, Nov. 6 GeoVax Labs, Inc. ... an Atlanta-based, biopharmaceutical company developing human vaccines for diseases ... agents, today announced its third quarter 2009 financial results ... President and Chief Executive Officer commented, "We are pleased ...
... PARIS, November 6 , ... Oral Agent Linezolid for the,Treatment of Multi-Resistant Staphylococcus Aureus ... speciality pharmaceutical company focused on the discovery and,development of ... microbial resistance, announces today that its most advanced oral,antibacterial ...
Cached Medicine Technology:GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4
(Date:1/22/2015)... January 22, 2015 Liberty University has received ... program from the Council for Accreditation of Counseling ... of Liberty’s Center for Counseling & Family Studies , ... of the university’s new School of Behavioral Sciences. Prior to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Gabe’s Chemo Duck Program ... App, the first app ever created for kids with cancer. The ... phones and devices, is filled with enjoyable games to help children ... treatments. The free app helps to keep kids entertained, educated and ...
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... Previous studies have shown that hepatitis C virus (HCV) ... than in whites. However, researchers demonstrate in this study, ... the American Association for the Study of Liver Diseases, ... recurrent HCV in the transplanted liver progresses faster in ...
... particular risk of their primary care physicians delaying diagnosis ... being presented at the American Society of Nephrology,s 42nd ... The findings suggest that educating practitioners about CKD ... to improvements in care to patients and savings in ...
... ,One Million Tests, World AIDS Day 2008 Campaign, AHF/Cambodia CARES ... 35,034 , PHNOM PENH, Cambodia, Oct. 31 As ... people for HIV in observance of the Testing ... will launch its inaugural testing effort during the annual Water ...
... suggests mortality rate may be linked to health-care inadequacies ... dementia are diagnosed with flu less often, have shorter ... die than those without dementia, says a U.S. study ... and older. , "The increased mortality of older patients ...
... , SAN FRANCISCO, Oct. 30 House speaker Nancy Pelosi ... Brown & Toland and a growing coalition of community groups ... epidemic. , Hepatitis B can cause liver cancer and ... Free campaign, of which Brown & Toland is a part, ...
... ... , ... 30, 2009 -- On Thursday this week, House Democratic leaders presented a new health care ... series of changes to accommodate lawmakers, concerns. In the Senate, Majority Leader Harry Reid (D-Nev.) ...
Cached Medicine News:Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 2Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 3Health News:Women with chronic kidney disease more likely than men to go undiagnosed 2Health News:Cambodia: World AIDS Day HIV Campaign, 'Testing Millions,' to Again Launch During Cambodia's National Water Festival 2Health News:Flu Deaths Higher Among Seniors With Dementia 2Health News:Brown & Toland Supports Fight Against Hepatitis B 2Health News:NAMI Applauds Initial Review of The Affordable Health Care of America Act and Health Care Reform 2Health News:NAMI Applauds Initial Review of The Affordable Health Care of America Act and Health Care Reform 3
DSL-10-49300 is a rapid, direct enzyme immunoassay (EIA) kit that provides materials for the quantitative measurement of testosterone in saliva. This assay requires no sample extraction or pretreat...
... biologically active form of Vitamin B6: ... prognostic marker for cardiovascular diseases. Recently, a ... level and Coronary Heart Disease (CHD) has ... to cystathionine and then to cystein are ...
... for use with 4, 8, or 12 channel ... of nearly all of the solution. Corners have ... of natural virgin polystyrene containing no regrinds. Sterile ... irradiation. Dimensions: 78 mm W x 152 mm ...
Volume: 10 ml; Volume Graduation: 1/10 ml...
Medicine Products: